Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
This article was originally published in The Pink Sheet Daily
Executive Summary
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
You may also be interested in...
Celgene Commences Thalomid Patent Litigation Against Barr
Lawsuit triggers 30-month stay of FDA action on generic thalidomide.
Celgene Commences Thalomid Patent Litigation Against Barr
Lawsuit triggers 30-month stay of FDA action on generic thalidomide.
Celgene Will Take Barr To Court Over Thalomid Patents
Barr filed an ANDA for thalidomide for erythema nodosum leprosum, although Celgene markets the drug more broadly for multiple myeloma.